Switch theme
Sign up to access all valuation multiples
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
1992
1.5K+
Last FY Revenue $221M
Last FY EBITDA $38.8M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, VCANBIO achieved revenue of $221M and an EBITDA of $38.8M.
VCANBIO expects next 12-month revenue of XXX and NTM EBITDA of XXX
See VCANBIO valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $221M | XXX | XXX | XXX |
| Gross Profit | XXX | $153M | XXX | XXX | XXX |
| Gross Margin | XXX | 69% | XXX | XXX | XXX |
| EBITDA | XXX | $38.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 18% | XXX | XXX | XXX |
| EBIT | XXX | $28.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 13% | XXX | XXX | XXX |
| Net Profit | XXX | $14.0M | XXX | XXX | XXX |
| Net Margin | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, VCANBIO's stock price is CNY 23 (or $3).
VCANBIO has current market cap of CNY 10.9B (or $1.5B), and EV of CNY 9.4B (or $1.3B).
See VCANBIO trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.5B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, VCANBIO has market cap of $1.5B and EV of $1.3B.
VCANBIO's trades at 5.9x EV/Revenue multiple, and 33.8x EV/EBITDA.
Equity research analysts estimate VCANBIO's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
VCANBIO's P/E ratio is not available.
See valuation multiples for VCANBIO and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 33.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 46.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 108.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 43.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVCANBIO's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
VCANBIO's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
VCANBIO's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for VCANBIO and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
VCANBIO acquired XXX companies to date.
Last acquisition by VCANBIO was XXXXXXXX, XXXXX XXXXX XXXXXX . VCANBIO acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was VCANBIO founded? | VCANBIO was founded in 1992. |
| Where is VCANBIO headquartered? | VCANBIO is headquartered in China. |
| How many employees does VCANBIO have? | As of today, VCANBIO has 1.5K+ employees. |
| Is VCANBIO publicy listed? | Yes, VCANBIO is a public company listed on SHG. |
| What is the stock symbol of VCANBIO? | VCANBIO trades under 600645 ticker. |
| When did VCANBIO go public? | VCANBIO went public in 1993. |
| Who are competitors of VCANBIO? | Similar companies to VCANBIO include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of VCANBIO? | VCANBIO's current market cap is $1.5B |
| Is VCANBIO profitable? | Yes, VCANBIO is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
